An
            <i>in silico</i>
            study of protein-protein interactions and design of novel peptides for TrkA in ameloblastoma

Mallick, Moyim; Yoithap Prabhunath, T. R.; Kumari, Sonia; Sobhia, M. Elizabeth

doi:10.1080/07391102.2023.2278083

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, two Phase I clinical trials (EUCTR2013-004009-25-GB, NCT02280317) did not show satisfactory results with VAL201 [174,175]. Through computer analysis, Mallick et al identified the key TrkA-binding peptide sequence of NGF and designed a hybrid peptide candidate that blocks the interaction between NGF and TrkA, which showed potential in the treatment of ameloblastoma [176]. Mulate et al used AlphaFold to identify various peptides targeting PKC [19].…”

Section: Protein-kinase Interaction Inhibitors (Pkiis)mentioning

confidence: 99%

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Li,

Gong,

Zhou

et al. 2024

IJMS

View full text Add to dashboard Cite

Over 120 small-molecule kinase inhibitors (SMKIs) have been approved worldwide for treating various diseases, with nearly 70 FDA approvals specifically for cancer treatment, focusing on targets like the epidermal growth factor receptor (EGFR) family. Kinase-targeted strategies encompass monoclonal antibodies and their derivatives, such as nanobodies and peptides, along with innovative approaches like the use of kinase degraders and protein kinase interaction inhibitors, which have recently demonstrated clinical progress and potential in overcoming resistance. Nevertheless, kinase-targeted strategies encounter significant hurdles, including drug resistance, which greatly impacts the clinical benefits for cancer patients, as well as concerning toxicity when combined with immunotherapy, which restricts the full utilization of current treatment modalities. Despite these challenges, the development of kinase inhibitors remains highly promising. The extensively studied tyrosine kinase family has 70% of its targets in various stages of development, while 30% of the kinase family remains inadequately explored. Computational technologies play a vital role in accelerating the development of novel kinase inhibitors and repurposing existing drugs. Recent FDA-approved SMKIs underscore the importance of blood–brain barrier permeability for long-term patient benefits. This review provides a comprehensive summary of recent FDA-approved SMKIs based on their mechanisms of action and targets. We summarize the latest developments in potential new targets and explore emerging kinase inhibition strategies from a clinical perspective. Lastly, we outline current obstacles and future prospects in kinase inhibition.

show abstract

Section: Protein-kinase Interaction Inhibitors (Pkiis)mentioning

confidence: 99%